NCT06526299View on ClinicalTrials.gov

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo SPECT/CT and CT

DRUG

Lutetium Lu 177 Vipivotide Tetraxetan

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

PSMA PET-CT Scan

Undergo PSMA PET/CT

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT/CT

Trial Locations (3)

91342

NOT_YET_RECRUITING

Olive View-University of California Los Angeles Medical Center, Sylmar

94143

NOT_YET_RECRUITING

University of California San Francisco, San Francisco

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mars Shot Research Fund

UNKNOWN

lead

University of Washington

OTHER

NCT06526299 - Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease | Biotech Hunter | Biotech Hunter